TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma

[1]  H. Miyata,et al.  Comprehensive registry of esophageal cancer in Japan, 2013 , 2020, Esophagus.

[2]  Sung-Bae Kim,et al.  Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[3]  Y. Tachimori,et al.  Comprehensive registry of esophageal cancer in Japan, 2012 , 2019, Esophagus.

[4]  R. Fisher,et al.  A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer. , 2019, Journal of Clinical Oncology.

[5]  Sung-Bae Kim,et al.  Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. , 2019, Journal of Clinical Oncology.

[6]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[7]  Manish R. Sharma,et al.  Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[9]  Joe Y. Chang,et al.  Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells , 2016, Clinical Cancer Research.

[10]  T. Kawano,et al.  Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303) , 2015, Cancer science.

[11]  Sean S. Park,et al.  PD-1 Restrains Radiotherapy-Induced Abscopal Effect , 2015, Cancer Immunology Research.

[12]  C. Drake,et al.  Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen , 2014, Cancer Immunology Research.

[13]  I. Stratford,et al.  Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.

[14]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[15]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[16]  Ping Zhang,et al.  Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. , 2008, Molecular immunology.

[17]  M. Shinoda,et al.  Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). , 2004, Japanese journal of clinical oncology.

[18]  S. Yoshida,et al.  Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.